Several randomized, placebo-controlled clinical trials have shown that patients with cancer who were treated with chemotherapy and prophylactic G-CSF experienced substantially less severe suppression of ANC, more rapid recovery of ANC, and lower incidence of infection (characterized by FN) than patients who did not receive prophylactic G-CSF [12, 25, 26]. The gene discussed is CSF3; the disease is cancer.